Loading cancer entity…
Loading cancer entity…
Clinical trials
3,386 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02628704 | Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma(SCORE) | withdrawn | Phase 2 | 0 | Karyopharm Therapeutics IncINDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 46 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2023 |
| clinicaltrials |
| NCT02593123 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | completed | Phase 2 | 31 | Virginia Commonwealth UniversityOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT01838369 | A Phase II Study of BI-505 in Smoldering Multiple Myeloma | terminated | Phase 2 | 4 | BioInvent International ABINDUSTRY | 1 | Jan 11, 2023 | clinicaltrials |
| NCT04287855 | Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma | unknown | Phase 2 | 82 | Poitiers University HospitalOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT00995059 | Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 5, 2023 | clinicaltrials |
| NCT02186834 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02440464 | Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | completed | Phase 2 | 57 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 4, 2023 | clinicaltrials |
| NCT03481556 | Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM(ANCHOR) | terminated | Phase 1 / Phase 2 | 56 | Oncopeptides ABINDUSTRY | 4 | Dec 19, 2022 | clinicaltrials |
| NCT01177397 | Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma | completed | Phase 1 / Phase 2 | 226 | CelgeneINDUSTRY | 4 | Dec 13, 2022 | clinicaltrials |
| NCT05594797 | Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM | recruiting | Phase 2 | 100 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT04223661 | Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy | withdrawn | Phase 2 | 0 | Attaya SuvannasankhaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT02963493 | A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma(HORIZON) | completed | Phase 2 | 157 | Oncopeptides ABINDUSTRY | 4 | Nov 22, 2022 | clinicaltrials |
| NCT01881789 | Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 22 | AmgenINDUSTRY | 1 | Nov 14, 2022 | clinicaltrials |
| NCT01416428 | Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 210 | AmgenINDUSTRY | 1 | Nov 8, 2022 | clinicaltrials |
| NCT02780609 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 4, 2022 | clinicaltrials |
| NCT02556931 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | completed | Phase 2 | 117 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02654132 | An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) | completed | Phase 2 | 117 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 1, 2022 | clinicaltrials |
| NCT02722941 | Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) | completed | Phase 2 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | not yet recruiting | Phase 1 / Phase 2 | 48 | Hellenic Society of HematologyOTHER | 0 | Oct 17, 2022 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01677858 | A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma(CHAMPION 1) | completed | Phase 1 / Phase 2 | 116 | AmgenINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT02415413 | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 90 | PETHEMA FoundationOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04552743 | MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma | completed | Phase 2 | 25 | Surbhi Sidana, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04277845 | Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma(KMM1910) | unknown | Phase 2 | 49 | Samsung Medical CenterOTHER | 1 | Sep 9, 2022 | clinicaltrials |
| NCT03336073 | Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma | unknown | Phase 2 | 199 | PETHEMA FoundationOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT00599495 | Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT | completed | Phase 2 | 50 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT05509374 | Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone(KMM2002) | unknown | Phase 2 | 33 | Samsung Medical CenterOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05509530 | Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM) | unknown | Phase 2 | 30 | Xuzhou Medical UniversityOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05497102 | Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT(KMM1911) | unknown | Phase 2 | 58 | Samsung Medical CenterOTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT00784823 | Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma(Mel-Vel) | completed | Phase 1 / Phase 2 | 32 | Hackensack Meridian HealthOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT01119066 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | completed | Phase 2 | 422 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04935580 | Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients | unknown | Phase 1 / Phase 2 | 20 | Shanghai Changzheng HospitalOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT01464034 | A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 136 | Criterium, Inc.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT02384083 | Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients | completed | Phase 1 / Phase 2 | 47 | PETHEMA FoundationOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT00464178 | A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 7 | Hackensack Meridian HealthOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT01555281 | Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | terminated | Phase 1 / Phase 2 | 33 | Swiss Cancer InstituteOTHER | 2 | Jul 7, 2022 | clinicaltrials |
| NCT04802031 | Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Thomas Martin, MDOTHER | 0 | Jul 7, 2022 | clinicaltrials |
| NCT04467281 | A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT02272803 | Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan | completed | Phase 2 | 82 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT03841565 | Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT02977494 | Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment(GMMG-DANTE) | completed | Phase 2 | 22 | Universitätsklinikum Hamburg-EppendorfOTHER | 2 | May 31, 2022 | clinicaltrials |
| NCT01849783 | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | completed | Phase 2 | 41 | Margarida Magalhaes-SilvermanOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT03256045 | Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT01463670 | Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance | completed | Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT01658241 | Panobinostat Biological Correlates Study(VEG VCA1) | completed | Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03303950 | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis | terminated | Phase 2 | 6 | University of UtahOTHER | 1 | May 5, 2022 | clinicaltrials |
| NCT05170789 | Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma(ESdRRMM) | withdrawn | Phase 2 | 0 | Tulane University School of MedicineOTHER | 0 | May 4, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Jan 26, 2023source: clinicaltrials